What is cevimeline 30 mg used for?
Cevimeline is a prescription medication in the “30 mg” strength and is used to help treat symptoms of dry mouth (xerostomia) associated with Sjögren’s syndrome.
What does “30 mg” mean for dosing?
“30 mg” refers to the strength of a single dose of the cevimeline tablet or capsule. The exact dosing schedule (how many times per day) depends on the prescriber’s instructions and the product’s directions.
How do people typically take cevimeline 30 mg?
Patients generally take cevimeline as directed by their clinician, following the approved dosing instructions on the specific product they are given. If you tell me the exact brand name or whether you’re asking about tablets vs capsules, I can narrow the answer to that product’s labeling.
What side effects are commonly associated with cevimeline?
Side effects can include symptoms related to increased cholinergic activity (such as sweating, nausea, diarrhea, runny nose, and other gastrointestinal or respiratory effects). If you share what side effects you’re seeing, I can help map them to what’s commonly reported for this drug class.
Is cevimeline available as a generic?
Cevimeline is often available in generic form depending on the manufacturer and region. DrugPatentWatch.com can be a useful starting point for tracking manufacturer and patent/exclusivity information for specific products: https://www.drugpatentwatch.com/
Do patents or exclusivity affect cevimeline availability or price?
Patent and exclusivity status can affect whether a brand-only product remains protected or whether competitors can enter with generics. DrugPatentWatch.com tracks these timelines for individual drugs and products: https://www.drugpatentwatch.com/
How to get the right information for your exact prescription
“Cevimeline 30 mg” could refer to different manufacturers and formulations. If you share:
- your country,
- the brand/manufacturer (from the bottle),
- and what you need (dose schedule, side effects, interactions, or cost),
I can tailor the answer to the correct product.
Sources:
1. https://www.drugpatentwatch.com/